FBXO22 antibody [N3C3]
GTX117774
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetFBXO22
Overview
- SupplierGeneTex
- Product NameFBXO22 antibody [N3C3]
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.29 mg/ml
- ConjugateUnconjugated
- Gene ID26263
- Target nameFBXO22
- Target descriptionF-box protein 22
- Target synonymsFBX22, FISTC1, TYMAS, F-box only protein 22, F-box protein FBX22p44, FIST domain containing 1
- HostRabbit
- IsotypeIgG
- Protein IDQ8NEZ5
- Protein NameF-box only protein 22
- Scientific DescriptionThis gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of the ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class. Two transcript variants encoding different isoforms exist for this gene. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Simoneschi D, Rona G, Zhou N, et al. CRL4(AMBRA1) is a master regulator of D-type cyclins. Nature. 2021,592(7856):789-793. doi: 10.1038/s41586-021-03445-yRead this paper
- Lignitto L, LeBoeuf SE, Homer H, et al. Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1. Cell. 2019,178(2):316-329.e18. doi: 10.1016/j.cell.2019.06.003Read this paper
- Johmura Y, Maeda I, Suzuki N, et al. Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. J Clin Invest. 2018,128(12):5603-5619. doi: 10.1172/JCI121679Read this paper


